Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
Open accessAbstract
Significance: Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes severe respiratory disease with a high mortality rate. There is no licensed vaccine or antiviral for MERS. Here we isolated for the first time, to our knowledge, a potent MERS-CoV–neutralizing antibody from memory B cells of an infected individual. This antibody binds to a novel site on the viral Spike protein, neutralizes by interfering with the binding to the cellular receptor CD26, and is highly effective both in prophylaxis and in therapy in a relevant mouse model. This antibody can be developed for prophylaxis, for postexposure prophylaxis, or for the treatment of severe MERS-CoV infections.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Human neutralizing antibodies protected mice challenged with SARS-CoV and MERS-CoV.
“previous reports have shown that human neutralizing antibodies protected mice challenged with SARS-CoV (12–14) and Middle East respiratory syndrome (MERS)-CoV (15)”
From An <i>Alphavirus</i> -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates (2020) · cites this paper as [15]
Cites
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677 · see citing works
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061 · see citing works
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
Ge, X.-Y., Li, J.-L., Yang, X.-L., Chmura, A. A., Zhu, G., Epstein, J. H., Mazet, J. K., Hu, B., Zhang, W., Peng, C., et al. (2013) · Nature · doi:10.1038/nature12711 · Cited by 1,778 · see citing works
Hospital outbreak of Middle East respiratory syndrome coronavirus
Assiri, A., McGeer, A., Perl, T. M., Price, C. S., Al Rabeeah, A. A., Cummings, D. A. T., Alabdullatif, Z. N., Assad, M., Almulhim, A., Makhdoom, H., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306742 · Cited by 1,196 · see citing works
Gray, J. J., Moughon, S. E., Wang, C., Schueler‐Furman, O., Kuhlman, B. A., Rohl, C. A., & Baker, D. A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00670-3 · Cited by 1,130 · see citing works
Tiller, T., Meffre, E., Yurasov, S., Tsuiji, M., Nussenzweig, M. C., & Wardemann, H. (2007) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.09.017 · Cited by 1,078 · see citing works
Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y., Wong, R. S. M., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P. K. S., Wong, K. C., Leung, C. B., & Cheng, G. Y.-M. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 953 · see citing works
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., Zhang, Y., Zhang, W., Yuan, Y., Bao, J., et al. (2013) · Nature · doi:10.1038/nature12328 · Cited by 732 · see citing works
Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., Guo, D., Fu, L., Cui, Y., Liu, X., et al. (2013) · Cell Research · doi:10.1038/cr.2013.92 · Cited by 717 · see citing works
Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia
Memish, Z. A., Mishra, N., Olival, K. J., Fagbo, S. F., Kapoor, V., Epstein, J. H., Alhakeem, R. F., Durosinloun, A., Asmari, M. A., Islam, A., et al. (2013) · Emerging infectious diseases · doi:10.3201/eid1911.131172 · Cited by 717 · see citing works
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697 · see citing works
Self-citationHung, I. F., To, K. K., Lee, C. K., Lee, K., Chan, K., Yan, W.-W., Liu, R. W., Watt, C., Chan, W.-M., Lai, K., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq106 · Cited by 679 · see citing works
Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
Haagmans, B. L., Dhahiry, S. H. S. A., Reusken, C. B. E. M., Raj, V. S., Galiano, M., Myers, R. E., Godeke, G.-J., Jonges, M., Farag, E., Diab, A. H. M., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70690-x · Cited by 672 · see citing works
Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?
Luke, T. C., Kilbane, E. M., Jackson, J. L., & Hoffman, S. L. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00139 · Cited by 637 · see citing works
Bermingham, A., Chand, M. A., Brown, C. S., Aarons, E., Tong, C. Y. W., Langrish, C., Höschler, K., Brown, K. E., Galiano, M., Myers, R. E., et al. (2012) · Eurosurveillance · doi:10.2807/ese.17.40.20290-en · Cited by 468 · see citing works
Self-citationRapid generation of a mouse model for Middle East respiratory syndrome
Zhao, J., Li, K., Wohlford-Lenane, C., Agnihothram, S., Fett, C., Zhao, J., Gale, M., Baric, R. S., Enjuanes, L., Gallagher, T., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323279111 · Cited by 453 · see citing works
Self-citationTreatment with Convalescent Plasma for Influenza A (H5N1) Infection
Zhou, B., Zhong, N., & Guan, Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070359 · Cited by 407 · see citing works
Gierer, S., Bertram, S., Kaup, F. ‐., Wrensch, F., Heurich, A., Krämer-Kühl, A., Welsch, K., Winkler, M., Meyer, B., Drosten, C., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00128-13 · Cited by 335 · see citing works
Ying, T., Du, L., Ju, T. W., Prabakaran, P., Lau, C. C. Y., Lu, L., Liu, Q., Wang, L., Feng, Y., Wang, Y., et al. (2014) · Journal of Virology · doi:10.1128/jvi.00912-14 · Cited by 233 · see citing works
Tang, X.-C., Agnihothram, S. S., Jiao, Y., Stanhope, J., Graham, R. L., Peterson, E. C., Avnir, Y., Tallarico, A. S. C., Sheehan, J., Zhu, Q., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402074111 · Cited by 232 · see citing works
Hofmann, H., Hattermann, K., Marzi, A., Gramberg, T., Geier, M., Krumbiegel, M., Kuate, S., Überla, K., Niedrig, M., & Pöhlmann, S. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6134-6142.2004 · Cited by 197 · see citing works
PIGS: automatic prediction of antibody structures
Marcatili, P., Rosi, A., & Tramontano, A. L. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn341 · Cited by 174 · see citing works
RosettaAntibody: antibody variable region homology modeling server
Sircar, A., Kim, E. T., & Gray, J. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp387 · Cited by 161 · see citing works
Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes
Temperton, N. J., Chan, P. K. S., Simmons, G., Zambon, M. C. F. A., Tedder, R. S., Takeuchi, Y., & Weiss, R. A. (2005) · Emerging infectious diseases · doi:10.3201/eid1103.040906 · Cited by 155 · see citing works
Self-citationA sensitive retroviral pseudotype assay for influenza H5N1‐neutralizing antibodies
Temperton, N. J., Höschler, K., Major, D., Nicolson, C., Manvell, R. J., Hien, V. M., Ha, D. Q., de Jong, M. D., Zambon, M. C. F. A., Takeuchi, Y., et al. (2007) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2007.00016.x · Cited by 142 · see citing works
Self-citationNebulization as a delivery method for mAbs in respiratory diseases
Respaud, R., Vecellio, L., Diot, P., & Heuzé‐Vourc'h, N. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.999039 · Cited by 140 · see citing works
Agnihothram, S., Gopal, R., Yount, B. L., Donaldson, E., Menachery, V. D., Graham, R. L., Scobey, T., Gralinski, L. E., Denison, M. R., Zambon, M. C. F. A., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit609 · Cited by 104 · see citing works
Self-citationLeyva-Grado, V. H., Tan, G. S., Leon, P. E., Yondola, M. A., & Palese, P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00290-15 · Cited by 75 · see citing works
Pedotti, M., Simonelli, L., Livoti, E., & Varani, L. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12010226 · Cited by 73 · see citing works
Self-citationThe Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors
Maillet, A., Guilleminault, L., Lemarié, É., Lerondel, S., Azzopardi, N., Montharu, J., Congy‐Jolivet, N., Reverdiau, P., Legrain, B., Parent, C., et al. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0442-5 · Cited by 72 · see citing works
Simonelli, L., Beltramello, M., Yudina, Z., Macagno, A., Calzolai, L., & Varani, L. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.12.053 · Cited by 36 · see citing works
Self-citationMERS surges again, but pandemic jitters ease
Kupferschmidt, K. (2015) · Science · doi:10.1126/science.347.6228.1296 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · see citing works
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510 · see citing works
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885 · see citing works
Self-citationCao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188 · see citing works
Potently neutralizing and protective human antibodies against SARS-CoV-2
Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041 · see citing works
Self-citationImmunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073 · see citing works
Structural insights into coronavirus entry
(2019) · Advances in Virus Research · doi:10.1016/bs.aivir.2019.08.002 · Cited by 769 · see citing works
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532 · see citing works
Self-citationUnexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion
Walls, A. C., Xiong, X., Park, Y.-J., Tortorici, M. A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.028 · Cited by 582 · see citing works
Self-citationLessons for COVID-19 immunity from other coronavirus infections
Sariol, A., & Perlman, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.005 · Cited by 317 · see citing works
Self-citationMERS-CoV spike protein: a key target for antivirals
Du, L., Yang, Y., Zhou, Y., Lu, L., Li, F., & Jiang, S. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1271415 · Cited by 301 · see citing works
Erasmus, J. H., Khandhar, A. P., O’Connor, M. A., Walls, A. C., Hemann, E. A., Murapa, P., Archer, J., Leventhal, S., Fuller, J. T., Lewis, T. B., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc9396 · Cited by 241 · see citing works
Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection
Menachery, V. D., Dinnon, K. H., Yount, B. L., McAnarney, E. T., Gralinski, L. E., Hale, A., Graham, R. L., Scobey, T., Anthony, S. J., Wang, L., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01774-19 · Cited by 205 · see citing works
Self-citationWang, L., Shi, W., Chappell, J. D., Joyce, M. G., Zhang, Y., Kanekiyo, M., Becker, M. M., van Doremalen, N., Fischer, R., Wang, N., et al. (2018) · Journal of Virology · doi:10.1128/jvi.02002-17 · Cited by 169 · see citing works
Widjaja, I., Wang, C., van Haperen, R., Gutiérrez-Álvarez, J., van Dieren, B., Okba, N. M. A., Raj, V. S., Li, W., Fernandez-Delgado, R., Grosveld, F., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1597644 · Cited by 115 · see citing works
Structural Definition of a Neutralization-sensitive Epitope on the MERS-CoV S1-NTD
Wang, N., Rosen, O., Wang, L., Turner, H. L., Stevens, L. J., Corbett, K. S., Bowman, C. A., Pallesen, J., Shi, W., Zhang, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.052 · Cited by 86 · see citing works
Chen, Y., Lu, S., Jia, H., Deng, Y., Zhou, J., Huang, B., Yu, Y., Lan, J., Wang, W., Lou, Y., et al. (2017) · Emerging Microbes & Infections · doi:10.1038/emi.2017.50 · Cited by 81 · see citing works
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395 · see citing works
Self-citation
- Authors
- Corti, D., Zhao, J., Pedotti, M., Simonelli, L., Agnihothram, S., Fett, C., Fernandez-Rodriguez, B., Foglierini, M., Agatic, G., Vanzetta, F., Gopal, R., Langrish, C. J., Barrett, N. A., Sallusto, F., Baric, R. S., Varani, L., Zambon, M., Perlman, S., & Lanzavecchia, A.
- Affiliations
- Institute for Research in Biomedicine (CH)
- University of Iowa (US)
- University of North Carolina at Chapel Hill (US)
- Humabs BioMed SA, 6500 Bellinzona, Switzerland;
- Public Health England (GB)
- Guy’s and St. Thomas’ National Health Service Foundation Trust, London SE1 7EH, United Kingdom;
- National Health Service (GB)
- ETH Zurich (CH)
- Corresponding author
- Corti, Davide
- Zhao, Jincun
- Lanzavecchia, Antonio
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-07-27
- Volume
- 112
- Issue
- 33
- Pages
- 10473-10478
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4547275
- OpenAlex
- W2137795918
- Cited by
- 216
- References
- 32
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 19 · 2023: 8 · 2022: 10 · 2021: 35 · 2020: 49 · 2019: 18 · 2018: 15 · 2017: 15 · 2016: 27 · 2015: 5
- FWCI
- 16.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Funders
- National Science Foundation
- Institute for Research in Biomedicine
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (138518, 147662)
- Public Health England
- Helmut Horten Stiftung
- Swiss Vaccine Research Institute
- National Institutes of Health (PO1AI060699, AI060699)
- U.S. Public Health Service (HHSN272201000013I)
- National Institute of Allergy and Infectious Diseases (PO1 AI060699, AI085524, AI110700, AI091322, R01AI085524, R01AI091322, HHSN272201000013C, R01AI110700, P01AI060699)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Keywords
- MERS coronavirus, monoclonal antibodies, neutralizing antibodies, spike protein, post-exposure prophylaxis, prophylaxis, memory B cells, antibody production, antiviral therapy, emerging viruses
- MeSH terms
- Amino Acid Sequence, Animals, Antibodies, Monoclonal, Antibodies, Viral, B-Lymphocytes, Binding Sites, Cricetulus, Enzyme-Linked Immunosorbent Assay, Female, Cricetinae, Humans, Immunologic Memory, Male, Mice, Inbred BALB C, Middle Aged, Molecular Conformation, Molecular Sequence Data, Mutation, Protein Binding, Viral Vaccines, CHO Cells, Sequence Homology, Amino Acid, Coronavirus Infections, Dipeptidyl Peptidase 4, Mice, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, Middle East Respiratory Syndrome Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
